0

News & Announcements - Generic Peptides

Stay updated with the latest news, product updates, research insights, and important announcements from Generic Peptides.

After Ozempic, FDA’s Next Peptide Fight Is Here: PSM Opposes All Seven Substances

After Ozempic, FDA’s Next Peptide Fight Is Here: PSM Opposes All Seven Substances

FDA Staff Recommends Against All Seven Peptides Before July PCAC Vote: Why That May Be a Bad Idea

FDA Staff Recommends Against All Seven Peptides Before July PCAC Vote: Why That May Be a Bad Idea

Epitalon and the FDA: Can the Insomnia Nomination Survive Scientific Review?

Epitalon and the FDA: Can the Insomnia Nomination Survive Scientific Review?

Semax Before the FDA: Cerebral Ischemia, Migraine and Trigeminal Neuralgia

Semax Before the FDA: Cerebral Ischemia, Migraine and Trigeminal Neuralgia

DSIP or Emideltide: Why FDA Is Reviewing the “Sleep Peptide”

DSIP or Emideltide: Why FDA Is Reviewing the “Sleep Peptide”

MOTS-c at the FDA: Obesity, Osteoporosis and the Missing Human Evidence

MOTS-c at the FDA: Obesity, Osteoporosis and the Missing Human Evidence

TB-500 Faces FDA Review: The Evidence Behind Its Wound-Healing Nomination

TB-500 Faces FDA Review: The Evidence Behind Its Wound-Healing Nomination

KPV and the FDA: Why Wound Healing and Inflammation Are Under Review

KPV and the FDA: Why Wound Healing and Inflammation Are Under Review

BPC-157 Goes Before the FDA: What the July 2026 Review Actually Means

BPC-157 Goes Before the FDA: What the July 2026 Review Actually Means

FDA Peptide Meeting July 2026: Seven Peptides, Two Days, and What Could Change

FDA Peptide Meeting July 2026: Seven Peptides, Two Days, and What Could Change

Peptide Boom 2026: Why Buyers Are Looking Beyond GLP-1s

Peptide Boom 2026: Why Buyers Are Looking Beyond GLP-1s

Pemvidutide's 48-Week Data: A Real MASH Contender — or Just Another Phase 2 Headline?

Pemvidutide's 48-Week Data: A Real MASH Contender — or Just Another Phase 2 Headline?